IL-AIT-WORLDWIDE
Global supply chain solutions leader, AIT Worldwide Logistics, is pleased to announce the launch of its new artificial intelligence (AI) and data science team, a corporate-level department created to amplify the organization’s investment in data. The team will set the stage for the future implementation of next-generation AI tools to further enhance the company’s robust customer interface. To lead the new group, AIT’s Patrick Chew has been appointed to vice president, AI and data science.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828389373/en/
Data is an integral pillar at AIT, with the new AI and data science team working to enable a new era of dramatic growth for the company. (Photo: Business Wire)
“AIT is continually looking towards the future,” said Chairman and Chief Executive Officer, Vaughn Moore. “With the establishment of the AI and data science team, the company is prepared to capitalize on generative AI, natural language processing, machine learning, large language models, and other advancing technologies.”
Over the course of 25 years, Chew has helped numerous Fortune 500 companies improve their business intelligence, analytics, and data enablement. He most recently served as the head of Caterpillar’s enterprise data governance office. Since joining the company in January 2024, Chew has been responsible for directing data enablement efforts. He reports to AIT’s President and Chief Operating Officer, Keith Tholan.
“AIT leadership has made a significant commitment to transform our data, and we are delighted to have Patrick in a role where he can leverage his vast experience to guide our ongoing data journey for the primary benefit of our customers and teammates,” Tholan said.
“Data is a common denominator that informs and impacts every aspect of the business,” he added. “And at AIT, our investment in taking data enablement to the next level clearly signals that data is an integral pillar of the organization, with the new AI and data science team working to enable a new era of dramatic growth for the company.”
The AI and data science group is comprised of three key teams:
- Data enablement – leading a disciplined, firmwide process to reorganize existing data strongholds into next-gen-compatible assets that will build new levels of trust with stakeholders through increased efficiency and ever-improving solutions
- AI governance and data science – developing new AI business features with an emphasis on heightened accuracy and privacy protections for customers and teammates as the technology continues to mature and evolve
- Business intelligence and analytics – providing dedicated, centralized reporting and visualization needs across the organization
The AI and data science team is implementing a regimented approach to transform data across AIT’s global network, including steps to redefine core domains and enhance time-tested workflows. Data management based on a newly configured single version of truth will be well-positioned to support powerful new key performance indicators.
“Treating data as an asset involves rigorous efforts to reorganize and harness millions of inputs, which will be applied in meaningful ways to enhance business intelligence, boost efficiency and spur innovation,” Chew said.
“Ambitiously raising the bar to loftier heights for data quality and governance ultimately improves outcomes for stakeholders as we continue to earn our customers’ trust,” he added. “Our AI and data science initiative will further differentiate AIT with shippers and investors when compared to others in the freight forwarding industry.”
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For more than 40 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, automotive, consumer retail, energy, food, government, high-tech, industrial, life sciences and marine. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes end-to-end deliveries via sea, air, ground and rail — on time and on budget. With expert teammates staffing more than 150 worldwide locations in Asia, Europe and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we vigorously seek opportunities to earn our customers’ trust by delivering exceptional worldwide logistics solutions while passionately valuing our co-workers, partners and communities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828389373/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom